NASDAQ:EXEL • US30161Q1040
EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. EXEL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. EXEL scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make EXEL a good candidate for value and quality investing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| ROIC | 29.21% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.48% | ||
| PM (TTM) | 33.73% | ||
| GM | 96.39% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.63 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.5 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.91 | ||
| Fwd PE | 13.56 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.49 | ||
| EV/EBITDA | 11.05 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
44.08
+0.16 (+0.36%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.91 | ||
| Fwd PE | 13.56 | ||
| P/S | 5.09 | ||
| P/FCF | 13.49 | ||
| P/OCF | 13.37 | ||
| P/B | 5.47 | ||
| P/tB | 5.63 | ||
| EV/EBITDA | 11.05 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| ROCE | 36.6% | ||
| ROIC | 29.21% | ||
| ROICexc | 51.64% | ||
| ROICexgc | 54.14% | ||
| OM | 38.48% | ||
| PM (TTM) | 33.73% | ||
| GM | 96.39% | ||
| FCFM | 37.75% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 29.01% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 95.93% | ||
| Profit Quality | 111.92% | ||
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.5 | ||
| Altman-Z | 12.63 |
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
EXELIXIS INC (EXEL) has a profitability rating of 9 / 10.
The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.
The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 17.33% in the next year.